<DOC>
	<DOCNO>NCT00577460</DOCNO>
	<brief_summary>The general aim study obtain long-term safety tolerability data pramipexole extend release ( ER ) , daily dose 0.375mg 4.5mg daily ( qd ) , patient previously complete pramipexole double-blind study advance Parkinson 's disease ( PD ) ( 248.525 trial ) .</brief_summary>
	<brief_title>Long-term Safety Study Open-label Pramipexole ER Patients With Advanced PD</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Completion doubleblind trial 248.525 2 . Male female patient advance idiopathic Parkinson 's disease ( PD ) , Modified Hoehn Yahr stage 2 4 ontime , concomitant treatment standard control release LDopa+ , combination LDopa+ entacapone . 3 . Patient willing able comply schedule visit , treatment plan , laboratory test study procedure . In particular patient able recognise offtime ontime period wake hour patient ( family member guardian ) able record accurately patient diary . 4 . Signed informed consent obtain study procedure carry ( accordance International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline local legislation ) . Exclusion criterion : 1 . Patients prematurely withdraw doubleblind trial 248.525 2 . Atypical parkinsonian syndrome due drug , metabolic disorder , encephalitis degenerative disease 3 . Any psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders ( DSM ) IV criterion could prevent compliance completion study and/or put patient risk he/she take part study 4 . History psychosis , except history drug induce hallucination 5 . History deep brain stimulation 6 . Clinically significant ECG abnormality baseline 7 . Clinically significant hypotension and/or symptomatic orthostatic hypotension baseline 8 . Malignant melanoma history previously treat malignant melanoma 9 . Any clinically significant disease , whether treat , could put patient risk could prevent compliance completion study 10 . Pregnancy breastfeed 11 . Sexually active female childbearing potential use medically approve method birth control 12 . Serum level aspartate transaminase ( AST ) ( serum glutamic oxaloacetic transaminase ( SGOT ) ) , alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase ) ( SGPT ) ) , alkaline phosphatase ( AP ) bilirubin &gt; 2 upper limit normal ( ULN ) baseline 13 . Patients creatinine clearance &lt; 50 mL/min baseline 14 . Any medication central dopaminergic antagonist activity within 4 week prior baseline visit 15 . Any following drug within 4 week prior baseline visit : methylphenidate , cinnarizine , amphetamines 16 . Flunarizine within 3 month prior baseline 17 . Known hypersensitivity pramipexole excipients 18 . Drug abuse , accord investigator judgement , within 2 year prior baseline 19 . Participation investigational drug study trial 248.525 , use investigational drug within one month five time halflife investigational drug ( whichever longer ) prior baseline</criteria>
	<gender>All</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>